Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.565 USD | +0.53% | -35.86% | -17.26% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.26% | 24Cr | |
+10.86% | 23TCr | |
+9.31% | 19TCr | |
+13.05% | 14TCr | |
+25.93% | 11TCr | |
+0.84% | 6.36TCr | |
+5.62% | 5.13TCr | |
+12.63% | 5.1TCr | |
+7.00% | 4.33TCr | |
+5.42% | 3.7TCr |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- JPMorgan Lowers Price Target for NeuroPace to $15 From $24, Maintains Overweight Rating